The effect of sinus node depression on heart rate variability in humans using zatebradine, a selective bradycardic agent

Canadian Journal of Physiology and Pharmacology

Volumn 76, Issue 7-8, 1998, Pages 806-810

  Khaykin, Yaariv ^a   Dorian, Paul ^a   Tang, Anthony ^b   Green, M ^b   Mitchell, Jan ^a   Wulffhart, Zaev ^a   Newman, David ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Autonomic nervous system; Heart rate variability; HRV; Sinus node; Zatebradine

Indexed keywords

SODIUM CHLORIDE; ZATEBRADINE;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART RATE VARIABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REENTRY TACHYCARDIA; SINUS NODE; SYMPATHETIC TONE;

EID: 0032458144     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y98-075     Document Type: Article

References (19)

1. Akselrod, S., Gordon, D., Ubel, F., Shannon, D.C., Barger, A., and Cohen, R.J. 1981. Power spectral analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science (Washington, D.C.), 213: 220-222.
2. Akselrod, S., Gordon, D., Madwed, J.B., Snidman, N.C., Shannon, D.C., and Cohen, R.J. 1985. Hemodynamic regulation: investigation by spectral analysis. Am. J. Physiol. 249: H867-H875.
3. Bailey, J.J., Berson, A.S., Garson, A., Jr., Horan, L.G., Macfarlane, P.W., Mortara, D.W., and Zywietz, C. 1990. Recommendations for standardization and specifications in automated electrocardiography. Circulation, 81: 730-739.
4. Bril, A., Faivre, J.F., and Gout, B. 1995. Zatebradine: pharmacological activity and potential therapeutic benefit of sino-atrial node modulators. Cardiovasc. Drug Rev. 13(4): 365-378.
5. f) in cells isolated from the rabbit sino-atrial node. J. Physiol. (London), 377: 61-88.
6. f. J. Cardiovasc. Electrophysiol. 3: 334-344.
7. f channel blocker. PACE, 19: 672.
8. Duong, N., Brinkl, R., and Nehmiz, G. 1991. Pharmacodynamic, pharmacokinetic and tolerability study of a single IV dose of UL FS 49 CL (rapid infusion of 5 mg in 5 min, followed by a maintenance infusion of 5 mg in 45 min) compared to placebo in healthy volunteers. Dr. Karl Thomae GmbH, study No. 140.55, draft report, June 1991, Boehringer-Ingleheim data on file, Ridgefield, Conn.
9. f in rabbit sinoatrial node cells by zatebradine (UL FS 49). Circulation, 88(1): 2389.
10. Golberger, J.J., Ahmed, M.W., Parker, M.A., and Kadish, A.H. 1994. Dissociation of heart rate variability from parasympathetic tone. Am. J. Physiol. 266: H2152-H2157.
11. Kobinger, W., and Lillie, C. 1984. Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-(3,4-dimethoxyphenyl)ethylimino[propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent." Eur. J. Pharmacol. 104: 9-18.
12. Lillie, C., and Kobinger, W. 1986. Investigations into the bradycardic effects of UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-(3,4-dimethoxyphenyl)ethylimino[propyl]-2H-3-benzazepin-2-on hydrochloride) in isolated guinea pig atria. J. Cardiovasc. Pharmacol. 8: 791-797.
13. Lippman, N., Stein, M.K., and Lerman, B.B. 1994. Comparison of methods for removal of ectopy in measurement of heart rate variability. Am. J. Physiol. 267: H411-H418.
14. Luczak, H., and Lauring, W.J. 1973. An analysis of heart rate variability. Ergonomics, 16: 85-97.
15. Malik, M. 1996. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation, 93: 1043-1065.
16. Pagani, M., Lombardi, F., Guzzetti, S., Rimoldi, O., Furlan, R., Pizzinelli, P., Sandrone, G., Malfatto, G., Dell'orto, S., Piccaluga, E., Turiel, M., Baselli, G., Cerutti, S., and Malliani, A. 1986. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympathovagal interaction in man and conscious dog. Circ. Res. 59: 178-193.
17. Pomeranz, B., Macaulay, R.J.B., Caudill, M.A., Kutz, I., Adam, D., Gordon, D., Kilborn, K.M., Barger, A.C., Shannon, D.C., Co sessment of autonomic function in humans by heart rate spectral analysis. Am. J. Physiol. 248: H151-H153.
18. Sayers, B.M. 1973. Analysis of heart rate variability. Ergonomics, 16: 17-32.
19. van Bogaert, P.P., and Goethals, M. 1992. Blockade of the pacemaker current by intracellular application of UL FS 49 CL and UL AH99 in sheep cardiac pacemaker fibers. Eur. J. Physiol. 421: 55-61.